mamacrowd-logo
InvestRaiseFund&CrowdGuideNews
LoginSign up
Biogenera
Biogenera | Mamacrowd

Biogenera

Biotech

Biotech company that has developed a unique and patented biotechnology platform to create new personalized DNA drugs to treat diseases that are incurable to date

  • Listing process, Paris Euronext stock exchange, in final stages

  • MyGenera platform to create new personalized DNA drugs

  • Drug BGA002 entering Clinical Phase 1 against pediatric cancers

  • Patents approved for 45 states, and designations by EMA and FDA agencies

TAX Bonus

Innov SME

    Project
    Team and Shareholders
    Market and Target
    Business Model
    Financial projections
    Use of funds
    Rewards for Investors
immagine copertina
The content of this page has been translated automatically

Project

BIOGENERA SpA is an innovative SME operating in the pharmaceutical biotechnology sector that has created and developed MyGenera, a unique and proprietary platform for a new era of patented personalized DNA drugs for the treatment of incurable diseases.

The company is in the final stages of its path to listing on Euronext Paris (Europe's most relevant market for biotech companies).

It counts on a multidisciplinary team of researchers and professionals and collaborates closely with universities and other players in the pharmaceutical industry. Its founders, Roberto Tonelli and Andrea Pession, have long careers as researchers and professors with a proven track record in pharmacology and oncology.

BIOGENERA currently has a portfolio of outright approved patents covering 45 countries internationally; in addition, Orphan Drug designations have been obtained from the European (EMA) and US (FDA) drug regulatory agencies.

Capital raising in the form of equity crowdfunding will support the costs for the multi-center Phase 1 clinical trial of the anti-cancer drug BGA002 for aggressive pediatric cancers in various European countries and the US.

It adopts a B2B business model and intends to finalize licensing agreements with pharmaceutical companies globally for the drug BGA002 (in clinical phase 1) and other new drugs for final clinical development and commercialization.

Tax benefits of 30 percent apply on Biogenera.

This is a marketing communication. Equity crowdfunding investments are high risk and could result in full or partial loss of invested capital. Please read the sheet containing key investment information before joining.

20240509080587_e5d5c4e9_7

Want to find out more about this project?

Register or log in, if you already have an account, to view all information in detail

Sign up
Login

Biogenera

Biotech

Closed 28/06/2024
funded

Total funding

1.583.424 €

Goal min 249,96k €

Goal max 5Mln €

504 investors

633% Goal min


Min order

527,00 €


Pre-Money

80,33Mln €

The information on the offer is not subject to approval by Consob. The Offering company is solely responsible for the completeness and truthfulness of the data and information provided by the latter. The investor's attention is also drawn to the fact that the investment, even indirect, through OICR or companies that invest mainly in financial instruments issued by innovative startups and SMEs is illiquid and characterised by a very high risk.
mamacrowd-logo

About us

Who we are

Press

Power User program

News

Carrers

Company informations

Real Estate Statistics

Crowdfunding services

Guide for the investor

Crowdfunding services

Investment costs

Risk warning

Alternative allowance regime

Tax benefits

Arbitrator for financial disputes

Dematerialized system

Trust company header service

Support

How to start

FAQ

Contacts

Terms & Conditions

Power User Terms & Conditions

Privacy Policy

Cookies Policy

Recovery Policy

Conflicts of Interest Policy

Handle Cookies

Warnings pursuant to art. 19 para. 2
the crowdfunding services provided by Mamacrowd do not fall under the deposit guarantee scheme established in accordance with Directive 2014/49/EU; the securities and instruments eligible for crowdfunding that can be acquired through this crowdfunding platform do not fall under the investor compensation scheme established in accordance with Directive 97/9/EC.

 

© 2025 Mamacrowd Srl a company of Azimut Group - VAT number IT07464370969 - Via Timavo 34, 20124 MI - SC € 95.417,54 fully paid up - Crowdfunding service provider authorised by resolution No. 22876 of 08/11/2023

  • Italiano

  • English

    Invest
      Invest in Startup/PMI and real estate projects
      Investor guide

    Raise
      Candidate a project

  • Italiano

  • English

Let us get to know you better

Mamacrowd and partners operate globally and can, upon acquiring your consent through the "Accept all", "Accept only necessary" or "Set preferences" commands, use cookies for statistical, advertising and also profiling purposes, own or third-party, to modulate the provision of the service in a personalized way and in line with your preferences.
In case of refusal we will only use the necessary cookies. For more information, read our Cookies Policy

Set preferences
Accept only necessary